T8	B-Entity	0	2	NF	NF	B-NP	NN	B-protein	3	NMOD	B-protein
T8	I-Entity	2	3	-	-	I-NP	HYPH	I-protein	3	NMOD	I-protein
T8	I-Entity	3	9	kappaB	kappaB	I-NP	NN	I-protein	4	NMOD	I-protein
O	O	10	20	activation	activation	I-NP	NN	O	5	SUB	O
O	O	21	23	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	24	25	a	a	B-NP	DT	O	8	NMOD	O
O	O	26	34	critical	critical	I-NP	JJ	O	8	NMOD	O
O	O	35	44	regulator	regulator	I-NP	NN	O	5	PRD	O
O	O	45	47	of	of	B-PP	IN	O	8	NMOD	O
O	O	48	53	human	human	B-NP	JJ	O	12	NMOD	O
O	O	54	65	granulocyte	granulocyte	I-NP	NN	O	12	NMOD	O
O	O	66	75	apoptosis	apoptosis	I-NP	NN	O	9	PMOD	O
O	O	76	78	in	in	B-ADVP	FW	O	5	VMOD	O
O	O	79	84	vitro	vitro	I-ADVP	FW	O	13	AMOD	O
O	O	84	85	.	.	O	.	O	5	P	O

O	O	87	93	During	During	B-PP	IN	O	10	VMOD	O
O	O	94	104	beneficial	beneficial	B-NP	JJ	O	3	NMOD	O
O	O	105	117	inflammation	inflammation	I-NP	NN	O	1	PMOD	O
O	O	117	118	,	,	O	,	O	10	P	O
O	O	119	130	potentially	potentially	B-NP	RB	O	9	NMOD	O
O	O	131	137	tissue	tissue	I-NP	NN	O	9	NMOD	O
O	O	137	138	-	-	B-NP	HYPH	O	6	P	O
O	O	138	146	damaging	damage	I-NP	VBG	O	9	NMOD	O
O	O	147	159	granulocytes	granulocyte	I-NP	NNS	B-cell_type	10	SUB	B-cell_type
O	O	160	167	undergo	undergo	B-VP	VBP	O	0	ROOT	O
O	O	168	177	apoptosis	apoptosis	B-NP	NN	O	10	OBJ	O
O	O	178	184	before	before	B-PP	IN	O	10	VMOD	O
O	O	185	190	being	be	B-VP	VBG	O	12	SBAR	O
O	O	191	198	cleared	clear	I-VP	VBN	O	13	VC	O
O	O	199	201	by	by	B-PP	IN	O	14	VMOD	O
O	O	202	212	phagocytes	phagocyte	B-NP	NNS	B-cell_type	15	PMOD	B-cell_type
O	O	213	215	in	in	B-PP	IN	O	16	NMOD	O
O	O	216	217	a	a	B-NP	DT	O	22	NMOD	O
O	O	218	221	non	non	I-NP	AFX	O	22	NMOD	O
O	O	221	222	-	-	I-NP	HYPH	O	22	NMOD	O
O	O	222	232	phlogistic	phlogistic	I-NP	JJ	O	22	NMOD	O
O	O	233	239	manner	manner	I-NP	NN	O	17	PMOD	O
O	O	239	240	.	.	O	.	O	10	P	O

O	O	241	245	Here	Here	B-ADVP	RB	O	3	VMOD	O
O	O	246	248	we	we	B-NP	PRP	O	3	SUB	O
O	O	249	253	show	show	B-VP	VBP	O	0	ROOT	O
O	O	254	258	that	that	B-SBAR	IN	O	3	VMOD	O
O	O	259	262	the	the	B-NP	DT	O	6	NMOD	O
O	O	263	267	rate	rate	I-NP	NN	O	15	SUB	O
O	O	268	270	of	of	B-PP	IN	O	6	NMOD	O
O	O	271	283	constitutive	constitutive	B-NP	JJ	O	9	NMOD	O
O	O	284	293	apoptosis	apoptosis	I-NP	NN	O	7	PMOD	O
O	O	294	296	in	in	B-PP	IN	O	9	NMOD	O
O	O	297	302	human	human	B-NP	JJ	B-cell_type	12	NMOD	B-cell_type
O	O	303	314	neutrophils	neutrophil	I-NP	NNS	I-cell_type	14	NMOD	I-cell_type
O	O	315	318	and	and	I-NP	CC	O	14	NMOD	O
O	O	319	330	eosinophils	eosinophil	I-NP	NNS	B-cell_type	10	PMOD	B-cell_type
O	O	331	333	is	be	B-VP	VBZ	O	4	SBAR	O
O	O	334	341	greatly	greatly	I-VP	RB	O	15	VMOD	O
O	O	342	353	accelerated	accelerate	I-VP	VBN	O	15	VC	O
O	O	354	356	in	in	B-PP	IN	O	17	VMOD	O
O	O	357	361	both	both	B-NP	CC	O	26	NMOD	O
O	O	362	363	a	a	I-NP	DT	O	23	NMOD	O
O	O	364	369	rapid	rapid	I-NP	JJ	O	23	NMOD	O
O	O	370	373	and	and	I-NP	CC	O	23	NMOD	O
O	O	374	387	concentration	concentration	I-NP	NN	O	26	NMOD	O
O	O	387	388	-	-	B-NP	HYPH	O	26	NMOD	O
O	O	388	397	dependent	dependent	I-NP	JJ	O	26	NMOD	O
O	O	398	404	manner	manner	I-NP	NN	O	18	PMOD	O
O	O	405	407	by	by	B-PP	IN	O	17	VMOD	O
O	O	408	411	the	the	B-NP	DT	O	31	NMOD	O
O	O	412	418	fungal	fungal	I-NP	JJ	O	31	NMOD	O
O	O	419	429	metabolite	metabolite	I-NP	NN	O	31	NMOD	O
O	O	430	439	gliotoxin	gliotoxin	I-NP	NN	O	27	PMOD	O
O	O	439	440	,	,	O	,	O	15	P	O
O	O	441	444	but	but	O	CC	O	15	VMOD	O
O	O	445	448	not	not	O	RB	O	35	PMOD	O
O	O	449	451	by	by	B-PP	IN	O	15	VMOD	O
O	O	452	455	its	its	B-NP	PRP$	O	39	NMOD	O
O	O	456	464	inactive	inactive	I-NP	JJ	O	39	NMOD	O
O	O	465	471	analog	analog	I-NP	NN	O	39	NMOD	O
O	O	472	491	methylthiogliotoxin	methylthiogliotoxin	I-NP	NN	O	35	PMOD	O
O	O	491	492	.	.	O	.	O	3	P	O

O	O	493	497	This	This	B-NP	DT	O	2	NMOD	O
O	O	498	507	induction	induction	I-NP	NN	O	5	SUB	O
O	O	508	510	of	of	B-PP	IN	O	2	NMOD	O
O	O	511	520	apoptosis	apoptosis	B-NP	NN	O	3	PMOD	O
O	O	521	524	was	be	B-VP	VBD	O	0	ROOT	O
O	O	525	534	abolished	abolish	I-VP	VBN	O	5	VC	O
O	O	535	537	by	by	B-PP	IN	O	6	VMOD	O
O	O	538	541	the	the	B-NP	DT	O	11	NMOD	O
O	O	542	549	caspase	caspase	I-NP	NN	O	11	NMOD	O
O	O	550	559	inhibitor	inhibitor	I-NP	NN	O	11	NMOD	O
O	O	560	564	zVAD	zVAD	I-NP	NN	O	13	NMOD	O
O	O	564	565	-	-	B-NP	HYPH	O	13	P	O
O	O	565	568	fmk	fmk	I-NP	NN	O	7	PMOD	O
O	O	568	569	,	,	O	,	O	5	P	O
O	O	570	580	correlated	correlate	B-VP	VBD	O	5	VMOD	O
O	O	581	585	with	with	B-PP	IN	O	15	VMOD	O
O	O	586	589	the	the	B-NP	DT	O	18	NMOD	O
O	O	590	600	inhibition	inhibition	I-NP	NN	O	16	PMOD	O
O	O	601	603	of	of	B-PP	IN	O	18	NMOD	O
T9	B-Entity	604	611	nuclear	nuclear	B-NP	JJ	B-protein	24	NMOD	B-protein
T9	I-Entity	612	618	factor	factor	I-NP	NN	I-protein	24	NMOD	I-protein
T9	I-Entity	618	619	-	-	B-NP	HYPH	I-protein	24	NMOD	I-protein
T9	I-Entity	619	624	kappa	kappa	I-NP	NN	I-protein	24	NMOD	I-protein
T9	I-Entity	625	626	B	B	I-NP	NN	I-protein	19	PMOD	I-protein
O	O	627	628	(	(	O	(	O	29	DEP	O
T10	B-Entity	628	630	NF	NF	B-NP	NN	B-protein	28	NMOD	B-protein
T10	I-Entity	630	631	-	-	B-NP	HYPH	I-protein	28	NMOD	I-protein
T10	I-Entity	631	637	kappaB	kappaB	I-NP	NN	I-protein	29	DEP	I-protein
O	O	637	638	)	)	O	)	O	24	NMOD	O
O	O	638	639	,	,	O	,	O	5	P	O
O	O	640	643	and	and	O	CC	O	5	VMOD	O
O	O	644	647	was	be	B-VP	VBD	O	5	VMOD	O
O	O	648	656	mimicked	mimic	I-VP	VBN	O	32	VC	O
O	O	657	659	by	by	B-PP	IN	O	33	VMOD	O
O	O	660	661	a	a	B-NP	DT	O	39	NMOD	O
T11	B-Entity	662	666	cell	cell	I-NP	NN	O	39	NMOD	O
T11	I-Entity	667	676	permeable	permeable	I-NP	JJ	O	39	NMOD	O
T11	I-Entity	677	687	inhibitory	inhibitory	I-NP	JJ	O	39	NMOD	O
T11	I-Entity	688	695	peptide	peptide	I-NP	NN	O	34	PMOD	O
O	O	696	698	of	of	B-PP	IN	O	39	NMOD	O
T12	B-Entity	699	701	NF	NF	B-NP	NN	B-protein	43	NMOD	B-protein
T12	I-Entity	701	702	-	-	B-NP	HYPH	I-protein	43	NMOD	I-protein
T12	I-Entity	702	708	kappaB	kappaB	I-NP	NN	I-protein	40	PMOD	I-protein
O	O	708	709	,	,	O	,	O	46	P	O
T13	B-Entity	710	712	SN	SN	B-NP	NN	B-protein	46	NMOD	B-protein
T13	I-Entity	712	713	-	-	B-ADJP	HYPH	O	39	NMOD	O
T13	I-Entity	713	715	50	50	B-NP	CD	O	46	NMOD	O
O	O	715	716	;	;	O	:	O	5	P	O
O	O	717	722	other	other	B-NP	JJ	O	53	NMOD	O
T14	B-Entity	723	725	NF	NF	I-NP	NN	B-protein	53	NMOD	B-protein
T14	I-Entity	725	726	-	-	B-NP	HYPH	I-protein	53	NMOD	I-protein
T14	I-Entity	726	732	kappaB	kappaB	I-NP	NN	I-protein	53	NMOD	I-protein
O	O	733	743	inhibitors	inhibitor	I-NP	NNS	O	58	NMOD	O
O	O	743	744	,	,	O	,	O	58	P	O
O	O	745	753	curcumin	curcumin	B-NP	NN	O	58	NMOD	O
O	O	754	757	and	and	I-NP	CC	O	58	NMOD	O
O	O	758	769	pyrrolidine	pyrrolidine	I-NP	NN	O	58	NMOD	O
O	O	770	785	dithiocarbamate	dithiocarbamate	I-NP	NN	O	5	VMOD	O
O	O	785	786	;	;	O	:	O	58	NMOD	O
O	O	787	790	and	and	O	CC	O	59	PMOD	O
O	O	791	794	the	the	B-NP	DT	O	63	NMOD	O
O	O	795	805	proteasome	proteasome	I-NP	NN	B-protein	63	NMOD	B-protein
O	O	806	815	inhibitor	inhibitor	I-NP	NN	O	65	NMOD	O
O	O	815	816	,	,	O	,	O	65	P	O
O	O	817	819	MG	MG	B-NP	NN	O	60	PMOD	O
O	O	819	820	-	-	B-NP	HYPH	O	65	P	O
O	O	820	823	132	132	I-NP	CD	O	65	NMOD	O
O	O	823	824	.	.	O	.	O	5	P	O

O	O	825	834	Gliotoxin	Gliotoxin	B-NP	NN	O	3	SUB	O
O	O	835	839	also	also	B-ADVP	RB	O	3	VMOD	O
O	O	840	849	augmented	augment	B-VP	VBD	O	0	ROOT	O
O	O	850	862	dramatically	dramatically	B-PP	RB	O	3	VMOD	O
O	O	863	866	the	the	B-NP	DT	O	6	NMOD	O
O	O	867	872	early	early	I-NP	JJ	O	3	OBJ	O
O	O	873	874	(	(	O	(	O	12	DEP	O
O	O	874	875	2	2	B-NP	CD	O	11	NMOD	O
O	O	875	876	-	-	I-NP	HYPH	O	11	NMOD	O
O	O	876	877	6	6	I-NP	CD	O	11	NMOD	O
O	O	878	879	h	h	I-NP	NN	O	12	DEP	O
O	O	879	880	)	)	O	)	O	6	NMOD	O
O	O	881	884	pro	pro	O	AFX	O	6	NMOD	O
O	O	884	885	-	-	O	HYPH	O	13	P	O
O	O	885	894	apoptotic	apoptotic	B-NP	JJ	O	16	NMOD	O
O	O	895	902	effects	effect	I-NP	NNS	O	14	OBJ	O
O	O	903	905	of	of	B-PP	IN	O	16	NMOD	O
T1	B-Protein	906	911	tumor	tumor	B-NP	NN	B-protein	22	NMOD	B-protein
T1	I-Protein	912	920	necrosis	necrosis	I-NP	NN	I-protein	22	NMOD	I-protein
T1	I-Protein	921	927	factor	factor	I-NP	NN	I-protein	22	NMOD	I-protein
T1	I-Protein	927	928	-	-	O	HYPH	I-protein	22	P	I-protein
T1	I-Protein	928	933	alpha	alpha	B-NP	SYM	I-protein	17	PMOD	I-protein
O	O	934	935	(	(	O	(	O	27	DEP	O
T2	B-Protein	935	938	TNF	TNF	B-NP	NN	B-protein	26	NMOD	B-protein
T2	I-Protein	938	939	-	-	B-NP	HYPH	I-protein	26	NMOD	I-protein
T2	I-Protein	939	944	alpha	alpha	I-NP	NN	I-protein	27	DEP	I-protein
O	O	944	945	)	)	O	)	O	22	NMOD	O
O	O	946	948	in	in	B-PP	IN	O	16	NMOD	O
O	O	949	960	neutrophils	neutrophil	B-NP	NNS	B-cell_type	28	PMOD	B-cell_type
O	O	961	964	and	and	O	CC	O	3	VMOD	O
O	O	965	973	unmasked	unmask	B-VP	VBD	O	3	VMOD	O
O	O	974	977	the	the	B-NP	DT	O	33	NMOD	O
O	O	978	985	ability	ability	I-NP	NN	O	31	OBJ	O
O	O	986	988	of	of	B-PP	IN	O	33	NMOD	O
T3	B-Protein	989	992	TNF	TNF	B-NP	NN	B-protein	34	PMOD	B-protein
T3	I-Protein	992	993	-	-	O	HYPH	O	37	P	O
T3	I-Protein	993	998	alpha	alpha	B-NP	SYM	O	35	NMOD	O
O	O	999	1001	to	to	B-VP	TO	O	39	VMOD	O
O	O	1002	1008	induce	induce	I-VP	VB	O	37	VMOD	O
O	O	1009	1019	eosinophil	eosinophil	B-NP	NN	B-cell_type	41	NMOD	B-cell_type
O	O	1020	1029	apoptosis	apoptosis	I-NP	NN	O	39	OBJ	O
O	O	1029	1030	.	.	O	.	O	3	P	O

O	O	1031	1033	In	In	B-PP	IN	O	7	VMOD	O
O	O	1034	1045	neutrophils	neutrophil	B-NP	NNS	B-cell_type	1	PMOD	B-cell_type
O	O	1045	1046	,	,	O	,	O	7	P	O
T4	B-Protein	1047	1050	TNF	TNF	B-NP	NN	B-protein	6	NMOD	B-protein
T4	I-Protein	1050	1051	-	-	O	HYPH	O	6	P	O
T4	I-Protein	1051	1056	alpha	alpha	B-NP	SYM	O	7	SUB	O
O	O	1057	1063	caused	cause	B-VP	VBD	O	0	ROOT	O
O	O	1064	1065	a	a	B-NP	DT	O	12	NMOD	O
O	O	1066	1075	gliotoxin	gliotoxin	I-NP	NN	O	12	NMOD	O
O	O	1075	1076	-	-	B-NP	HYPH	O	12	NMOD	O
O	O	1076	1087	inhibitable	inhibitable	I-NP	JJ	O	12	NMOD	O
O	O	1088	1098	activation	activation	I-NP	NN	O	7	OBJ	O
O	O	1099	1101	of	of	B-PP	IN	O	12	NMOD	O
O	O	1102	1104	an	an	B-NP	DT	O	16	NMOD	O
O	O	1105	1114	inducible	inducible	I-NP	JJ	O	16	NMOD	O
O	O	1115	1119	form	form	I-NP	NN	O	23	NMOD	O
O	O	1120	1122	of	of	B-PP	IN	O	16	NMOD	O
T15	B-Entity	1123	1125	NF	NF	B-NP	NN	B-protein	20	NMOD	B-protein
T15	I-Entity	1125	1126	-	-	B-NP	HYPH	I-protein	20	NMOD	I-protein
T15	I-Entity	1126	1132	kappaB	kappaB	I-NP	NN	I-protein	17	PMOD	I-protein
O	O	1132	1133	,	,	O	,	O	23	P	O
O	O	1134	1135	a	a	B-NP	DT	O	23	NMOD	O
O	O	1136	1144	response	response	I-NP	NN	O	13	PMOD	O
O	O	1145	1149	that	that	B-NP	WDT	O	12	NMOD	O
O	O	1150	1153	may	may	B-VP	MD	O	24	SBAR	O
O	O	1154	1162	underlie	underlie	I-VP	VB	O	25	VC	O
O	O	1163	1166	the	the	B-NP	DT	O	28	NMOD	O
O	O	1167	1174	ability	ability	I-NP	NN	O	26	OBJ	O
O	O	1175	1177	of	of	B-PP	IN	O	28	NMOD	O
T5	B-Protein	1178	1181	TNF	TNF	B-NP	NN	B-protein	29	PMOD	B-protein
T5	I-Protein	1181	1182	-	-	O	HYPH	O	34	VMOD	O
T5	I-Protein	1182	1187	alpha	alpha	B-NP	SYM	O	34	P	O
O	O	1188	1190	to	to	B-VP	TO	O	34	VMOD	O
O	O	1191	1196	delay	delay	I-VP	VB	O	30	NMOD	O
O	O	1197	1206	apoptosis	apoptosis	B-NP	NN	O	34	OBJ	O
O	O	1207	1209	at	at	B-PP	IN	O	34	VMOD	O
O	O	1210	1215	later	later	B-NP	JJ	O	38	NMOD	O
O	O	1216	1221	times	time	I-NP	NNS	O	36	PMOD	O
O	O	1222	1223	(	(	O	(	O	44	DEP	O
O	O	1223	1225	12	12	B-NP	CD	O	43	NMOD	O
O	O	1225	1226	-	-	I-NP	HYPH	O	43	NMOD	O
O	O	1226	1228	24	24	I-NP	CD	O	43	NMOD	O
O	O	1229	1230	h	h	I-NP	NN	O	44	DEP	O
O	O	1230	1231	)	)	O	)	O	30	NMOD	O
O	O	1232	1235	and	and	O	CC	O	26	VMOD	O
O	O	1236	1241	limit	limit	B-VP	VB	O	26	VMOD	O
O	O	1242	1245	its	its	B-NP	PRP$	O	50	NMOD	O
O	O	1246	1251	early	early	I-NP	JJ	O	50	NMOD	O
O	O	1252	1259	killing	killing	I-NP	NN	O	50	NMOD	O
O	O	1260	1266	effect	effect	I-NP	NN	O	46	OBJ	O
O	O	1266	1267	.	.	O	.	O	7	P	O

O	O	1268	1279	Furthermore	Furthermore	B-ADVP	RB	O	4	VMOD	O
O	O	1279	1280	,	,	O	,	O	4	P	O
O	O	1281	1294	cycloheximide	cycloheximide	B-NP	NN	O	4	SUB	O
O	O	1295	1304	displayed	display	B-VP	VBD	O	0	ROOT	O
O	O	1305	1306	a	a	B-NP	DT	O	7	NMOD	O
O	O	1307	1314	similar	similar	I-NP	JJ	O	7	NMOD	O
O	O	1315	1323	capacity	capacity	I-NP	NN	O	4	OBJ	O
O	O	1324	1326	to	to	B-VP	TO	O	9	VMOD	O
O	O	1327	1334	enhance	enhance	I-VP	VB	O	7	NMOD	O
T6	B-Protein	1335	1338	TNF	TNF	B-NP	NN	B-protein	12	NMOD	B-protein
T6	I-Protein	1338	1339	-	-	B-NP	HYPH	I-protein	12	P	I-protein
T6	I-Protein	1339	1344	alpha	alpha	I-NP	SYM	I-protein	13	AMOD	I-protein
O	O	1345	1352	induced	induce	I-NP	VBN	O	15	NMOD	O
O	O	1353	1363	neutrophil	neutrophil	I-NP	NN	B-cell_type	15	NMOD	B-cell_type
O	O	1364	1373	apoptosis	apoptosis	I-NP	NN	O	9	OBJ	O
O	O	1374	1378	even	even	B-ADVP	RB	O	17	PMOD	O
O	O	1379	1381	at	at	B-PP	IN	O	4	VMOD	O
O	O	1382	1386	time	time	B-NP	NN	O	19	NMOD	O
O	O	1387	1393	points	point	I-NP	NNS	O	17	PMOD	O
O	O	1394	1398	when	when	B-ADVP	WRB	O	19	NMOD	O
O	O	1399	1412	cycloheximide	cycloheximide	B-NP	NN	O	23	SUB	O
O	O	1413	1418	alone	alone	B-ADVP	RB	O	21	NMOD	O
O	O	1419	1422	had	have	B-VP	VBD	O	20	SBAR	O
O	O	1423	1425	no	no	B-NP	DT	O	28	NMOD	O
O	O	1426	1429	pro	pro	I-NP	AFX	B-DNA	28	NMOD	B-DNA
O	O	1429	1430	-	-	I-NP	HYPH	O	28	NMOD	O
O	O	1430	1439	apoptotic	apoptotic	I-NP	JJ	O	28	NMOD	O
O	O	1440	1446	effect	effect	I-NP	NN	O	23	OBJ	O
O	O	1446	1447	,	,	O	,	O	17	P	O
O	O	1448	1458	suggesting	suggest	B-VP	VBG	O	17	PMOD	O
O	O	1459	1463	that	that	B-SBAR	IN	O	30	VMOD	O
T16	B-Entity	1464	1466	NF	NF	B-NP	NN	B-protein	34	NMOD	B-protein
T16	I-Entity	1466	1467	-	-	B-NP	HYPH	I-protein	34	NMOD	I-protein
T16	I-Entity	1467	1473	kappaB	kappaB	I-NP	NN	I-protein	35	SUB	I-protein
O	O	1474	1477	may	may	B-VP	MD	O	31	SBAR	O
O	O	1478	1486	regulate	regulate	I-VP	VB	O	35	VC	O
O	O	1487	1490	the	the	B-NP	DT	O	38	NMOD	O
O	O	1491	1501	production	production	I-NP	NN	O	36	OBJ	O
O	O	1502	1504	of	of	B-PP	IN	O	38	NMOD	O
O	O	1505	1512	protein	protein	B-NP	NN	O	42	NMOD	O
O	O	1512	1513	(	(	B-NP	(	O	42	NMOD	O
O	O	1513	1514	s	s	I-NP	NNS	O	39	PMOD	O
O	O	1514	1515	)	)	O	)	O	42	NMOD	O
O	O	1516	1521	which	which	B-NP	WDT	O	42	NMOD	O
O	O	1522	1529	protect	protect	B-VP	VBP	O	44	SBAR	O
O	O	1530	1541	neutrophils	neutrophil	B-NP	NNS	B-cell_type	45	OBJ	B-cell_type
O	O	1542	1546	from	from	B-PP	IN	O	45	VMOD	O
O	O	1547	1550	the	the	B-NP	DT	O	50	NMOD	O
O	O	1551	1560	cytotoxic	cytotoxic	I-NP	JJ	O	50	NMOD	O
O	O	1561	1568	effects	effect	I-NP	NNS	O	47	PMOD	O
O	O	1569	1571	of	of	B-PP	IN	O	50	NMOD	O
T7	B-Protein	1572	1575	TNF	TNF	B-NP	NN	B-protein	54	NMOD	B-protein
T7	I-Protein	1575	1576	-	-	O	HYPH	O	54	P	O
T7	I-Protein	1576	1581	alpha	alpha	B-NP	SYM	O	51	PMOD	O
O	O	1581	1582	.	.	O	.	O	4	P	O

O	O	1583	1588	These	These	B-NP	DT	O	2	NMOD	O
O	O	1589	1593	data	datum	I-NP	NNS	O	3	SUB	O
O	O	1594	1598	shed	shed	B-VP	VBD	O	0	ROOT	O
O	O	1599	1604	light	light	B-NP	NN	O	3	OBJ	O
O	O	1605	1607	on	on	B-PP	IN	O	3	VMOD	O
O	O	1608	1611	the	the	B-NP	DT	O	10	NMOD	O
O	O	1612	1623	biochemical	biochemical	I-NP	JJ	O	10	NMOD	O
O	O	1624	1627	and	and	I-NP	CC	O	10	NMOD	O
O	O	1628	1637	molecular	molecular	I-NP	JJ	O	10	NMOD	O
O	O	1638	1648	mechanisms	mechanism	I-NP	NNS	O	5	PMOD	O
O	O	1649	1659	regulating	regulate	B-VP	VBG	O	10	NMOD	O
O	O	1660	1665	human	human	B-NP	JJ	O	14	NMOD	O
O	O	1666	1677	granulocyte	granulocyte	I-NP	NN	O	14	NMOD	O
O	O	1678	1687	apoptosis	apoptosis	I-NP	NN	O	11	OBJ	O
O	O	1688	1691	and	and	O	CC	O	3	VMOD	O
O	O	1691	1692	,	,	O	,	O	3	P	O
O	O	1693	1695	in	in	B-PP	IN	O	3	VMOD	O
O	O	1696	1706	particular	particular	B-ADJP	JJ	O	17	PMOD	O
O	O	1706	1707	,	,	O	,	O	3	P	O
O	O	1708	1716	indicate	indicate	B-VP	VBP	O	3	VMOD	O
O	O	1717	1721	that	that	B-SBAR	IN	O	20	VMOD	O
O	O	1722	1725	the	the	B-NP	DT	O	24	NMOD	O
O	O	1726	1739	transcription	transcription	I-NP	NN	B-protein	24	NMOD	B-protein
O	O	1740	1746	factor	factor	I-NP	NN	I-protein	27	NMOD	I-protein
T17	B-Entity	1747	1749	NF	NF	I-NP	NN	B-protein	27	NMOD	B-protein
T17	I-Entity	1749	1750	-	-	B-NP	HYPH	I-protein	27	NMOD	I-protein
T17	I-Entity	1750	1756	kappaB	kappaB	I-NP	NN	I-protein	28	SUB	I-protein
O	O	1757	1762	plays	play	B-VP	VBZ	O	21	SBAR	O
O	O	1763	1764	a	a	B-NP	DT	O	31	NMOD	O
O	O	1765	1772	crucial	crucial	I-NP	JJ	O	31	NMOD	O
O	O	1773	1777	role	role	I-NP	NN	O	28	OBJ	O
O	O	1778	1780	in	in	B-PP	IN	O	28	VMOD	O
O	O	1781	1791	regulating	regulate	B-VP	VBG	O	32	PMOD	O
O	O	1792	1795	the	the	B-NP	DT	O	38	NMOD	O
O	O	1796	1809	physiological	physiological	I-NP	JJ	O	38	NMOD	O
O	O	1810	1814	cell	cell	I-NP	NN	O	38	NMOD	O
O	O	1815	1820	death	death	I-NP	NN	O	38	NMOD	O
O	O	1821	1828	pathway	pathway	I-NP	NN	O	33	OBJ	O
O	O	1829	1831	in	in	B-PP	IN	O	38	NMOD	O
O	O	1832	1844	granulocytes	granulocyte	B-NP	NNS	B-cell_type	39	PMOD	B-cell_type
O	O	1844	1845	.	.	O	.	O	3	P	O
